Report Detail
Global Remicade Biosimilar Market Insights, Forecast to 2025
- RnM2440416 |
- 04 June, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product.
The global Remicade Biosimilar market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Remicade Biosimilar market based on company, product type, end user and key regions.
This report studies the global market size of Remicade Biosimilar in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Remicade Biosimilar in these regions.
This research report categorizes the global Remicade Biosimilar market by top players/brands, region, type and end user. This report also studies the global Remicade Biosimilar market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Synthon Pharmaceuticals
LG Life Sciences
Novartis (Sandoz)
Celltrion
Biocon
Hospira
Merck Serono (Merck Group)
Biogen idec Inc.
Genentech (Roche Group)
Market size by Product
100mg/10ml
500mg/50ml
Market size by End User
Blood Disorders
Oncology Diseases
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Remicade Biosimilar market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Remicade Biosimilar market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Remicade Biosimilar companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Remicade Biosimilar submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Remicade Biosimilar are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Remicade Biosimilar market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Remicade Biosimilar Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Remicade Biosimilar Market Size Growth Rate by Product
- 1.4.2 100mg/10ml
- 1.4.3 500mg/50ml
- 1.5 Market by End User
- 1.5.1 Global Remicade Biosimilar Market Size Growth Rate by End User
- 1.5.2 Blood Disorders
- 1.5.3 Oncology Diseases
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Remicade Biosimilar Market Size
- 2.1.1 Global Remicade Biosimilar Revenue 2014-2025
- 2.1.2 Global Remicade Biosimilar Sales 2014-2025
- 2.2 Remicade Biosimilar Growth Rate by Regions
- 2.2.1 Global Remicade Biosimilar Sales by Regions
- 2.2.2 Global Remicade Biosimilar Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Remicade Biosimilar Sales by Manufacturers
- 3.1.1 Remicade Biosimilar Sales by Manufacturers
- 3.1.2 Remicade Biosimilar Sales Market Share by Manufacturers
- 3.1.3 Global Remicade Biosimilar Market Concentration Ratio (CR5 and HHI)
- 3.2 Remicade Biosimilar Revenue by Manufacturers
- 3.2.1 Remicade Biosimilar Revenue by Manufacturers (2014-2019)
- 3.2.2 Remicade Biosimilar Revenue Share by Manufacturers (2014-2019)
- 3.3 Remicade Biosimilar Price by Manufacturers
- 3.4 Remicade Biosimilar Manufacturing Base Distribution, Product Types
- 3.4.1 Remicade Biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Remicade Biosimilar Product Type
- 3.4.3 Date of International Manufacturers Enter into Remicade Biosimilar Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Remicade Biosimilar Sales by Product
- 4.2 Global Remicade Biosimilar Revenue by Product
- 4.3 Remicade Biosimilar Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Remicade Biosimilar Breakdown Data by End User
6 North America
- 6.1 North America Remicade Biosimilar by Countries
- 6.1.1 North America Remicade Biosimilar Sales by Countries
- 6.1.2 North America Remicade Biosimilar Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Remicade Biosimilar by Product
- 6.3 North America Remicade Biosimilar by End User
7 Europe
- 7.1 Europe Remicade Biosimilar by Countries
- 7.1.1 Europe Remicade Biosimilar Sales by Countries
- 7.1.2 Europe Remicade Biosimilar Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Remicade Biosimilar by Product
- 7.3 Europe Remicade Biosimilar by End User
8 Asia Pacific
- 8.1 Asia Pacific Remicade Biosimilar by Countries
- 8.1.1 Asia Pacific Remicade Biosimilar Sales by Countries
- 8.1.2 Asia Pacific Remicade Biosimilar Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Remicade Biosimilar by Product
- 8.3 Asia Pacific Remicade Biosimilar by End User
9 Central & South America
- 9.1 Central & South America Remicade Biosimilar by Countries
- 9.1.1 Central & South America Remicade Biosimilar Sales by Countries
- 9.1.2 Central & South America Remicade Biosimilar Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Remicade Biosimilar by Product
- 9.3 Central & South America Remicade Biosimilar by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Remicade Biosimilar by Countries
- 10.1.1 Middle East and Africa Remicade Biosimilar Sales by Countries
- 10.1.2 Middle East and Africa Remicade Biosimilar Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Remicade Biosimilar by Product
- 10.3 Middle East and Africa Remicade Biosimilar by End User
11 Company Profiles
- 11.1 Synthon Pharmaceuticals
- 11.1.1 Synthon Pharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Synthon Pharmaceuticals Remicade Biosimilar Products Offered
- 11.1.5 Synthon Pharmaceuticals Recent Development
- 11.2 LG Life Sciences
- 11.2.1 LG Life Sciences Company Details
- 11.2.2 Company Business Overview
- 11.2.3 LG Life Sciences Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 LG Life Sciences Remicade Biosimilar Products Offered
- 11.2.5 LG Life Sciences Recent Development
- 11.3 Novartis (Sandoz)
- 11.3.1 Novartis (Sandoz) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Novartis (Sandoz) Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Novartis (Sandoz) Remicade Biosimilar Products Offered
- 11.3.5 Novartis (Sandoz) Recent Development
- 11.4 Celltrion
- 11.4.1 Celltrion Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Celltrion Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Celltrion Remicade Biosimilar Products Offered
- 11.4.5 Celltrion Recent Development
- 11.5 Biocon
- 11.5.1 Biocon Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Biocon Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Biocon Remicade Biosimilar Products Offered
- 11.5.5 Biocon Recent Development
- 11.6 Hospira
- 11.6.1 Hospira Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Hospira Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Hospira Remicade Biosimilar Products Offered
- 11.6.5 Hospira Recent Development
- 11.7 Merck Serono (Merck Group)
- 11.7.1 Merck Serono (Merck Group) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Merck Serono (Merck Group) Remicade Biosimilar Products Offered
- 11.7.5 Merck Serono (Merck Group) Recent Development
- 11.8 Biogen idec Inc.
- 11.8.1 Biogen idec Inc. Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Biogen idec Inc. Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Biogen idec Inc. Remicade Biosimilar Products Offered
- 11.8.5 Biogen idec Inc. Recent Development
- 11.9 Genentech (Roche Group)
- 11.9.1 Genentech (Roche Group) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Genentech (Roche Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Genentech (Roche Group) Remicade Biosimilar Products Offered
- 11.9.5 Genentech (Roche Group) Recent Development
12 Future Forecast
- 12.1 Remicade Biosimilar Market Forecast by Regions
- 12.1.1 Global Remicade Biosimilar Sales Forecast by Regions 2019-2025
- 12.1.2 Global Remicade Biosimilar Revenue Forecast by Regions 2019-2025
- 12.2 Remicade Biosimilar Market Forecast by Product
- 12.2.1 Global Remicade Biosimilar Sales Forecast by Product 2019-2025
- 12.2.2 Global Remicade Biosimilar Revenue Forecast by Product 2019-2025
- 12.3 Remicade Biosimilar Market Forecast by End User
- 12.4 North America Remicade Biosimilar Forecast
- 12.5 Europe Remicade Biosimilar Forecast
- 12.6 Asia Pacific Remicade Biosimilar Forecast
- 12.7 Central & South America Remicade Biosimilar Forecast
- 12.8 Middle East and Africa Remicade Biosimilar Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Remicade Biosimilar Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Remicade Biosimilar . Industry analysis & Market Report on Remicade Biosimilar is a syndicated market report, published as Global Remicade Biosimilar Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Remicade Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
